Kristen M. Pettit, MD

Articles by Kristen M. Pettit, MD

Key Takeaways: Optimal Use of JAK Inhibitors in MF and Future Directions in Care

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 25th 2023

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Patient Scenario 2: A 68-Year-Old Woman With Anemic MF

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 18th 2023

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

Sequencing of JAK Inhibitors in Patients With Myelofibrosis

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 18th 2023

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

Myelofibrosis: Dosing JAK Inhibitors and Managing Adverse Events

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 11th 2023

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.

JAK Inhibitors in Patients With Cytopenic Myelofibrosis

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 11th 2023

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

Value of JAK Inhibitors in Myelofibrosis Management

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 4th 2023

A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.

Patient Scenario 1: A 72-Year-Old Man With Primary Myelofibrosis

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

August 4th 2023

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.

Myelofibrosis Management: Current Treatment Guidelines

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

July 28th 2023

Expert panelists share brief insight on the current NCCN guidelines for selecting treatment in patients with myelofibrosis.

Selecting Transplantation Versus Systemic Therapy in Myelofibrosis

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

July 28th 2023

Focused discussion on the factors that help to select patients for stem cell transplantation over systemic therapy in the setting of myelofibrosis.

Evolving Role of Transplantation in Myelofibrosis

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

July 21st 2023

A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.

Biomarkers in Myelofibrosis: LDH, BMF, and Triple-Negative Disease

ByJohn O. Mascarenhas, MD,Gabriela S. Hobbs, MD,Kristen M. Pettit, MD,Andrew T. Kuykendall, MD

July 21st 2023

Key opinion leaders in myelofibrosis management reflect on the role of biomarkers in informing treatment selection, even for patients with triple-negative disease.